Form 4: Akari Therapeutics Director James R. Neal Acquires 2,000,000 Ordinary Shares

Director James R. Neal of Akari Therapeutics Plc reports the acquisition of 2,000,000 ordinary shares at a price of $0.0005 per share on December 23, 2024.

Summary

• On December 26, 2024, a Form 4 filing was submitted to the SEC by Torsten Hombeck, as Attorney-in-Fact, on behalf of James R. Neal, a director of Akari Therapeutics Plc.
• The filing reports a transaction that occurred on December 23, 2024, where Mr. Neal acquired 2,000,000 ordinary shares of Akari Therapeutics at a price of $0.0005 per share.
• Following this transaction, Mr. Neal directly owns 24,216,000 ordinary shares.

Sentiment

Score: 6

Explanation: The sentiment is neutral. It's a report of a transaction, and while insider buying can be seen as positive, it's a single transaction and doesn't provide enough information to strongly indicate a positive outlook.

Positives

• A director's purchase of shares can be seen as a positive signal, indicating confidence in the company's future prospects.

Industry Context

This filing is a routine disclosure required by the SEC when a company insider, such as a director, buys or sells shares in their own company. It provides transparency to the market regarding insider transactions.

Stakeholder Impact

• The acquisition of shares by a director could potentially increase investor confidence.

Key Dates